Problematic Prostatic Prediction
Michael Davidson
Abstract
Michael Davidson
Abstract
To the Editor.— Chodak and Schoenberg1address the important issue of efficacy of prostate cancer screening by digital rectal examination but have mislabeled an important parameter of that test. The authors repeatedly refer to a test "specificity of 29%" erroneously calculated as (true test positives/true test positives+false test positives) and compared it with that reported by others. The value they calculated was really the positive predictive value. The specificity of a test should represent the percentage of negative tests among patients free of disease (true test negatives/true test negatives+false test positives). Unless an appropriate gold standard is available to distinguish those individuals who are truly test negative from those with early undetectable disease (false test negatives), the specificity of a screening test must assume a low disease prevalence with a few false-negatives "contaminating" both the numerator and denominator. The high prevalence in older men of microscopic prostate cancers (almost
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
To the Editor.— Chodak and Schoenberg1address the important issue of efficacy of prostate cancer screening by digital rectal examination but have mislabeled an important parameter of that test. The authors repeatedly refer to a test "specificity of 29%" erroneously calculated as (true test positives/true test positives+false test positives) and compared it with that reported by others. The value they calculated was really the positive predictive value. The specificity of a test should represent the percentage of negative tests among patients free of disease (true test negatives/true test negatives+false test positives). Unless an appropriate gold standard is available to distinguish those individuals who are truly test negative from those with early undetectable disease (false test negatives), the specificity of a screening test must assume a low disease prevalence with a few false-negatives "contaminating" both the numerator and denominator. The high prevalence in older men of microscopic prostate cancers (almost
Key concepts: False positive paradox, Medicine, Test (biology), False Negative Reactions, Predictive value, False positives and false negatives, Gold standard (test), Prostate cancer